Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunocore Holdings plc - American Depositary Shares (NQ: IMCR ) 29.18 -1.04 (-3.44%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Immunocore Holdings plc - American Depositary Shares < Previous 1 2 3 4 5 6 Next > Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME December 23, 2024 From Immunocore Holdings plc Via GlobeNewswire Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers December 17, 2024 From Immunocore Holdings plc Via GlobeNewswire Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? December 13, 2024 Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks. Via Benzinga EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma December 11, 2024 From Immunocore Holdings plc Via GlobeNewswire Navigating 8 Analyst Ratings For Immunocore Hldgs November 11, 2024 Via Benzinga A Closer Look at 9 Analyst Recommendations For Immunocore Hldgs October 24, 2024 Via Benzinga Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma December 03, 2024 From Immunocore Holdings plc Via GlobeNewswire 3 Fast-Growing Stocks Analysts See Doubling in Price November 11, 2024 Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches. Via MarketBeat Immunocore to present at upcoming investor conferences November 08, 2024 From Immunocore Holdings plc Via GlobeNewswire Analyst Ratings For Immunocore Hldgs October 07, 2024 Via Benzinga Analyst Expectations For Immunocore Hldgs's Future September 17, 2024 Via Benzinga The Latest Analyst Ratings For Immunocore Hldgs August 28, 2024 Via Benzinga Deep Dive Into Immunocore Hldgs Stock: Analyst Perspectives (9 Ratings) August 09, 2024 Via Benzinga Immunocore reports third quarter financial results and provides a business update November 06, 2024 From Immunocore Holdings plc Via GlobeNewswire GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday September 17, 2024 Via Benzinga Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer September 14, 2024 From Immunocore Holdings plc Via GlobeNewswire Immunocore to present at the 2024 Cantor Global Healthcare Conference September 12, 2024 From Immunocore Holdings plc Via GlobeNewswire Peeling Back The Layers: Exploring Immunocore Hldgs Through Analyst Insights July 10, 2024 Via Benzinga Analyst Expectations For Immunocore Hldgs's Future May 24, 2024 Via Benzinga Immunocore announces transition of Chief Financial Officer August 29, 2024 From Immunocore Holdings plc Via GlobeNewswire Immunocore reports second quarter financial results and provides a business update August 08, 2024 From Immunocore Holdings plc Via GlobeNewswire 3 Small-Cap Stocks with Significant Growth Potential August 06, 2024 As sector rotation continues, it could be time for investors to consider these small-cap growth stocks that institutions love. Via InvestorPlace Immunocore to report second quarter 2024 financial results and host call on August 8, 2024 August 01, 2024 From Immunocore Holdings plc Via GlobeNewswire Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma June 18, 2024 From Immunocore Holdings plc Via GlobeNewswire Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session June 03, 2024 Via Benzinga Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response June 01, 2024 From Immunocore Holdings plc Via GlobeNewswire Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 May 31, 2024 From Immunocore Holdings plc Via GlobeNewswire Immunocore to present at the Jefferies Global Healthcare Conference May 30, 2024 From Immunocore Holdings plc Via GlobeNewswire Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma May 29, 2024 From Immunocore Holdings plc Via GlobeNewswire Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session May 24, 2024 Via Benzinga < Previous 1 2 3 4 5 6 Next > Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
